[Form 4] BIO-TECHNE Corp Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Bio-Techne director Amy E. Herr reported routine equity activity on 02/03/2026, mainly involving awards held by her significant other. On that date, 38 restricted stock units converted into 38 shares of common stock at $0, all held indirectly through her significant other.
To cover withholding obligations, 16 indirectly held common shares were disposed of at $64.63 per share, leaving 2,176 common shares indirectly held by her significant other and 2,680 shares held directly. The filing also lists multiple stock options and additional restricted stock units with vesting dates from 2026 through 2035, all either directly held or indirectly held through her significant other.
Positive
- None.
Negative
- None.
Insider Trade Summary
38 shares exercised/converted
Mixed
17 txns
Insider
Herr Amy E.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 38 | $0.00 | -- |
| Exercise | Common Stock | 38 | $0.00 | -- |
| Tax Withholding | Common Stock | 16 | $64.63 | $1K |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 77 shares (Indirect, By significant other);
Common Stock — 2,192 shares (Indirect, By significant other);
Stock Option (Right to Buy) — 2,415 shares (Direct);
Stock Option (Right to Buy) — 6,636 shares (Indirect, By significant other);
Common Stock — 2,680 shares (Direct)
Footnotes (1)
- This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. Fully vested. Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026. Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027. Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028. Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. 118 restricted stock units vest on 8/15/2026. 160 restricted stock units vest on each of 8/15/2026 and 8/15/2027. 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028. 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028. Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
